secwatch.observer — SEC 8-K summary
======================================

Issuer:     NKGen Biotech, Inc. (—)
CIK:        0001845459
Form:       8-K
Filed at:   2026-05-21T21:20:15+00:00
Accession:  0001213900-26-060160
Event type: debt
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 2.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NKGen Biotech gets $412.5K additional convertible loan at $0.08/share; increases consideration shares to 12.15M
--------------------------------------------------------------------------------

- Additional loan of $412,500 (net $375,000) from AlpineBrook Capital; convertible at $0.08/share and warrant exercisable at $0.08/share.
- Consideration shares increased to 12,147,280, to be delivered in five installments over 25 months.
- Voting agreement with major shareholders to support increase in authorized shares for conversion and warrant exercise.
- Loan matures on Maturity Date under existing Loan Agreement; interest at Applicable Rate, 360-day year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1845459/000121390026060160/0001213900-26-060160-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1845459/000121390026060160/ea0291582-8k_nkgen.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-060160

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer